REG - ValiRx PLC - ValiSeek Clinical Development Update <Origin Href="QuoteRef">VALX.L</Origin>

ValiRxAnnouncement

16/07/2015 15:35

RNS Number : 1837T
ValiRx PLC
16 July 2015
16 July 2015
ValiRx Plc
("ValiRx" or the "Company")
ValiSeek Clinical Development Update 
Further to the announcement of 14 May 2015, ValiRx Plc (AIM: VAL) is pleased to announce that it has initiated the process for a late stage (Phase 2b) clinical trial of its lung cancer drug, VAL401, at ValiSeek Limited ("ValiSeek"), its joint venture with Tangent Reprofiling Limited, formed to progress the compound towards Clinical Efficacy trials.
A clinical trial contract has been established between ValiSeek and Clinical Accelerator, a UK-based clinical trial management organisation, to manage and execute the Phase 2b Clinical Trial in patients with non-small-cell lung adenocarcinoma.
The parameters to be assessed during the trial will include (i) effectiveness of the treatment (as observed by measurements of disease progression, quality of life and survival); (ii) pharmacokinetics of VAL401 and (iii) safety and tolerability of the VAL401 treatment in the patient population. 
Dr Suzanne Dilly, CEO of ValiSeek Limited, commented:"We look forward to benefiting from this collaboration with the specialist team at Clinical Accelerator, both in terms of seeking to fast-track VAL401 into the patient population and accelerating the clinical process. I look forward to providing updates on the clinical start-up phase throughout the remainder of 2015."
Dr Satu Vainikka, CEO of ValiRx plc, added: "As the second ValiRx product to enter the clinical trial process, I look forward to seeing the potential of the VAL401 project being crystallised through the collection of a first set of real world patient data."
For more information, please contact:
ValiRx plc
Tel: +44 (0) 20 3008 4416
Dr Satu Vainikka
www.valirx.com


Cairn Financial Advisers LLP (Nominated Adviser)
Tel: +44 (0) 20 7148 7900
Liam Murray / Avi Robinson



Northland Capital Partners Limited (Broker)
Tel: +44 (0) 20 7382 1100
Patrick Claridge / David Hignell (Corporate Finance)
John Howes / Abigail Wayne (Broking)

Peckwater PR
Tel: +44 (0) 7879 458 364
Tarquin Edwards
tarquin.edwards@peckwaterpr.co.uk
Notes for Editors 
About Clinical Accelerator
Clinical Accelerator is an independent clinical trial management organisation operating principally in Central and Eastern Europe, Russia, Ukraine and CIS countries. The organisation offers a broad range of clinical trial services together with dedicated patient enrolment support to worldwide clients in the pharmaceutical, biotechnology, nutraceutical and medical device industries. Clinical Accelerator's model of operation is designed to achieve significant cost savings for its clients and to guarantee compact timelines for patient enrolment with a firm focus on the quality of clinical trial data.
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications
About SEEK
Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low costs medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.
Additional information about SEEK is available on the Company's website located at www.seekacure.com
ValiRx Plc
ValiRx Plc is a biopharmaceutical company developing novel technologies and products in oncology therapeutics and diagnostics. The product focus is in the epigenomic analysis and treatment of cancer, but the technologies can be applied to other fields as well, such as neurology and inflammatory diseases.
The Company has undertaken todevelop a novel and groundbreaking class of therapeutics across a number offields in oncology and has taken its lead compound, Val201, into Phase I/IIclinicaltrials. The Company listed onthe Alternative Investment Market ("AIM") of the London StockExchange in October 2006.
The Company has a pipeline ofother therapeutic drugs, which are currently progressing towards clinicaltrials. The product focus is in the targeted analysis and treatment of cancer,but thetechnologies can be applied to other fields as well, such as neurologyand inflammatory diseases.
It actively manages projectswithin its portfolio as a trading company. The ValiRx business model spreads the risks of life science technologydevelopment by minimising financial exposure andrunning a set of projects todefined commercial endpoints. This maximises returns to shareholders by adding value at the earlier stages where value increases per investment unit are thegreatest.
The Company operates through thefollowing divisional companies:
1. ValiPharma is the therapeuticsdivision, with two embedded technologies primarily directed at the treatment ofcancers.
2. ValiFinn is the biomarkers anddiagnostic development division. ValiRxacquired through its ValiFinn subsidiary, the complimentary TRAC technologylater in the year to strengthen the portfolio.
3. ValiSeek is a joint venturebetween ValiRx and Tangent Ltd to develop Val401 in lung cancer and potentiallyother indications.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
MSCBCGDRCDBBGUU